MedTrace Logo

Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Gingival Recession Defects

NCT04361630 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-05-01

No results posted yet for this study

Summary

This study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the treatment of Miller's class I and class II gingival recessions.

Conditions

  • Periodontitis

Interventions

DRUG

FGF 2

Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.

Sponsors & Collaborators

  • SVS Institute of Dental Sciences

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2019-11-01
Completion
2019-12-01

Countries

  • India

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04361630 on ClinicalTrials.gov